Squarepoint
DAWN

Squarepoint’s Day One Biopharmaceuticals DAWN Stock Holding History

Squarepoint’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.91M Buy
415,706
+315,094
+313% +$4.44M 0.01% 1135
2025
Q4 		$938K Buy
+100,612
New +$841K ﹤0.01% 2671
2025
Q2 		– Sell
-41,326
Closed -$328K – 4595
2025
Q1 		$328K Buy
41,326
+11,297
+38% +$122K ﹤0.01% 3673
2024
Q4 		$380K Buy
+30,029
New +$418K ﹤0.01% 3971
2024
Q3 		– Sell
-186,484
Closed -$2.57M – 4209
2024
Q2 		$2.57M Buy
+186,484
New +$2.73M ﹤0.01% 1856
2024
Q1 		– Sell
-15,927
Closed -$233K – 4136
2023
Q4 		$233K Sell
15,927
-30,917
-66% -$375K ﹤0.01% 3504
2023
Q3 		$575K Sell
46,844
-114,942
-71% -$1.5M ﹤0.01% 2686
2023
Q2 		$1.93M Sell
161,786
-62,191
-28% -$812K 0.01% 1676
2023
Q1 		$2.99M Buy
223,977
+193,161
+627% +$3.77M 0.01% 1157
2022
Q4 		$663K Buy
+30,816
New +$632K ﹤0.01% 2104
2021
Q3 		– Sell
-18,927
Closed -$431K – 3003
2021
Q2 		$431K Buy
+18,927
New +$395K ﹤0.01% 2252

Other funds holding DAWN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
KC
Kryger Capital London, United Kingdom $1.41B AUM 86.31% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

Squarepoint's DAWN Position: Q1 2026 in Review

Squarepoint increased its Day One Biopharmaceuticals (DAWN) stake by 313% in Q1 2026, buying an estimated $4.44M and bringing the position to 415,706 shares worth $8.91M. The position accounts for 0.01% of the portfolio, ranked #1135.

Squarepoint first reported a position in DAWN in Q2 2021 and has held it in 11 quarters since. 206 funds tracked by Wall St. Rank hold DAWN as of Q1 2026.

  • Squarepoint held 415,706 shares of Day One Biopharmaceuticals worth $8.91M as of Q1 2026.
  • Squarepoint bought 315,094 Day One Biopharmaceuticals shares in Q1 2026, an estimated $4.44M.
  • Day One Biopharmaceuticals made up 0.01% of Squarepoint's portfolio in Q1 2026, its #1135 holding.
  • Squarepoint first reported a position in Day One Biopharmaceuticals in Q2 2021 and has held it in 11 quarters since.
  • 206 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.